or

[ASAP] Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00082




or

[ASAP] Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00192




or

[ASAP] Exploration of the Structural Space in 4(3<italic toggle="yes">H</italic>)-Quinazolinone Antibacterials

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00153




or

[ASAP] Drug Research Meets Network Science: Where Are We?

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.9b01989




or

[ASAP] Discovery and Optimization of Glucose Uptake Inhibitors

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.9b02153




or

[ASAP] Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin—Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00441




or

[ASAP] Discovery of Selective, Covalent FGFR4 Inhibitors with Antitumor Activity in Models of Hepatocellular Carcinoma

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00601




or

[ASAP] Chimeric Peptidomimetics of SOCS 3 Able to Interact with JAK2 as Anti-inflammatory Compounds

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00664




or

[ASAP] Progress in the Field of Aldehyde Dehydrogenase Inhibitors: Novel Imidazo[1,2-<italic toggle="yes">a</italic>]pyridines against the 1A Family

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00686




or

[ASAP] Inhibitors of Hypoxia-Inducible Factors as Treatment for Cancer

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00116




or

[ASAP] Glycans Meet Sphingolipids: Structure-Based Design of Glycan Containing Analogues of a Sphingosine Kinase Inhibitor

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00665




or

[ASAP] Synthesis of Novel G Factor or Chloroquine-Artemisinin Hybrids and Conjugates with Potent Antiplasmodial Activity

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00669




or

[ASAP] Novel HIV-1 Protease Inhibitors with Morpholine as the P2 Ligand to Enhance Activity against DRV-Resistant Variants

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00043




or

[ASAP] Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00045




or

[ASAP] Characterization of an Alginate Encapsulated LS180 Spheroid Model for Anti-colorectal Cancer Compound Screening

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00076




or

[ASAP] Structure Optimization of Gatastatin for the Development of ?-Tubulin-Specific Inhibitor

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00526




or

[ASAP] Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00625




or

[ASAP] Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00111




or

[ASAP] Pharmacophore-Based Virtual Screening for Identification of Negative Modulators of GLI1 as Potential Anticancer Agents

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00639




or

[ASAP] Exploring the Implication of DDX3X in DENV Infection: Discovery of the First-in-Class DDX3X Fluorescent Inhibitor

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00681




or

[ASAP] Discovery of BMS-986251: A Clinically Viable, Potent, and Selective ROR?t Inverse Agonist

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00063




or

[ASAP] Combined Peptide and Small-Molecule Approach toward Nonacidic THIQ Inhibitors of the KEAP1/NRF2 Interaction

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00594




or

[ASAP] New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00561




or

[ASAP] Novel Dithiolane-Based Ligands Combining Sigma and NMDA Receptor Interactions as Potential Neuroprotective Agents

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00129




or

[ASAP] Selective Covalent Targeting of Mutated EGFR(T790M) with Chlorofluoroacetamide-Pyrimidines

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00574




or

[ASAP] Design and Synthesis of Tetrazole- and Pyridine-Containing Itraconazole Analogs as Potent Angiogenesis Inhibitors

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00438




or

[ASAP] Potential Cancer Treatment by Agonists of the Stimulator of Interferon Genes

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00117




or

[ASAP] Artemisinin Derivatives with Antimelanoma Activity Show Inhibitory Effect against Human DNA Topoisomerase 1

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00131




or

[ASAP] Discovery of a Potent Dual Inhibitor of Wild-Type and Mutant Respiratory Syncytial Virus Fusion Proteins

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00008




or

[ASAP] Sigma Receptor Ligands Carrying a Nitric Oxide Donor Nitrate Moiety: Synthesis, In Silico, and Biological Evaluation

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00661




or

[ASAP] Characterization of Specific <italic toggle="yes">N</italic>-a-Acetyltransferase 50 (Naa50) Inhibitors Identified Using a DNA Encoded Library

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00029




or

[ASAP] Discovery of an Atropisomeric PI3Kß Selective Inhibitor through Optimization of the Hinge Binding Motif

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00095




or

[ASAP] Can Drug Repositioning Work as a Systematical Business Model?

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00122




or

[ASAP] Update to Our Reader, Reviewer, and Author Communities—April 2020

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00206




or

[ASAP] Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300/CBP Histone Acetyltransferase Inhibitor

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00155




or

[ASAP] PROTAC Compounds Targeting a-Synuclein Protein for Treating Neurogenerative Disorders: Alzheimer’s and Parkinson’s Diseases

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00192




or

[ASAP] Development of Selective Steroid Inhibitors for the Glucose-6-phosphate Dehydrogenase from <italic toggle="yes">Trypanosoma cruzi</italic>

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00106




or

[ASAP] P2Y<sub>14</sub> Receptor Antagonists Reverse Chronic Neuropathic Pain in a Mouse Model

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00115




or

[ASAP] Discovery of RO7185876, a Highly Potent ?-Secretase Modulator (GSM) as a Potential Treatment for Alzheimer’s Disease

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00109




or

[ASAP] Ultra-High-Throughput Acoustic Droplet Ejection-Open Port Interface-Mass Spectrometry for Parallel Medicinal Chemistry

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00066




or

[ASAP] Discovery of Adamantane Carboxamides as Ebola Virus Cell Entry and Glycoprotein Inhibitors

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00025




or

[ASAP] Benzoxazepine-Derived Selective, Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00092




or

[ASAP] Scaffold Repurposing of in-House Chemical Library toward the Identification of New Casein Kinase 1 d Inhibitors

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00028




or

[ASAP] Development of a Raltegravir-based Photoaffinity-Labeled Probe for Human Immunodeficiency Virus-1 Integrase Capture

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00009




or

[ASAP] Substituted Azabicyclo[2.2.1]heptanes as Selective Orexin-1 Antagonists: Discovery of JNJ-54717793

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00085




or

[ASAP] Synthesis and Evaluation of <sup>11</sup>C- and <sup>18</sup>F-Labeled SOAT1 Inhibitors as Macrophage Foam Cell Imaging Agents

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00127




or

[ASAP] Ligand Design for Cereblon Based Immunomodulatory Therapy

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00214




or

Solar Trees Powering The Park Of South Florida

Joining South Florida’s lush, green canopy of real trees are a new crop of solar trees. These “trees” have blue trunks and bear no fruit, but supply clean energy to whoever needs it. If you’re at the beach and your phone starts to die, you can charge it right here using Solar Power. Here’s how …

The post Solar Trees Powering The Park Of South Florida appeared first on LatestSolarNews.




or

Solar Powered Lights For The Yard

Reading about the various sofas reviews here and choosing amongst them to match your patio is not that difficult when compared to doing the entire electrical work of the patio. When you are lighting your patio the exact opposite thing you need to do is to be stumbling over electrical lines and attempting to put …

The post Solar Powered Lights For The Yard appeared first on LatestSolarNews.




or

Sono Motors Introduces The SION Solar Powered Car

The fantasy of having the capacity to drive to work in a solar-powered car is at last turning into a reality. Sono Motors simply uncovered the SION solar-powered electric car gives you the ability to travel up to 18 miles utilizing only energy from the sun. Best of all, the SION isn’t only for the …

The post Sono Motors Introduces The SION Solar Powered Car appeared first on LatestSolarNews.